AMITYVILLE, N.Y.--(BUSINESS WIRE)--Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK) announced that the Company will market buprenorphine HCl 2mg and 8mg sublingual tablets, the generic for Reckitt Benckiser’s Subutex® sublingual tablets through its Midlothian Laboratories division. Sales in the buprenorphine HCl 2mg and 8mg sublingual tablet market reached $75 million for the 12 months ended June 2010 according to IMS. EthyPharm, the Company’s development and manufacturing partner for this product received final approval for its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration. The product is indicated for the treatment of opiod dependence. The Company plans to launch generic buprenorphine HCl immediately. Hi-Tech will receive a percentage of net sales and a share of the profits.
